肿瘤坏死百分之九十及以上与骨肉瘤患者生存及健康社会决定因素相关:基于美国国家癌症数据库的分析
该研究基于美国国家癌症数据库(NCDB)2006例骨肉瘤患者中纳入分析的1580例,评估化疗后肿瘤坏死百分比与生存的关系。结果显示90%坏死是预后最佳 cutoff,低于90%坏死与更差生存相关(HR 2.00),且无保险、低社会经济地位等健康社会决定因素与达到90%以上坏死负相关。
要点
- 90%至94%坏死与95%至100%坏死的5年总生存无差异(p=0.47)。
- 坏死低于90%与更差生存相关(HR 2.00,95%CI 1.58至2.52,p<0.001)。
- 无保险与较低社会经济地位复合评分与达到90%以上坏死负相关。
核心结论
- 本研究提示90%坏死 cutoff 为接受化疗的骨肉瘤患者提供最佳预后价值,其他阈值未显示不同生存获益。
- 社会人口学因素与低于90%的组织学反应相关,这些关联不应被理解为因果关系,而可能反映健康差异和医疗可及性的影响。
研究设计与样本
- 回顾性分析美国国家癌症数据库(NCDB)中2010年至2015年诊断的2006例骨肉瘤患者,排除肿瘤坏死百分比记录缺失者(21%,425/2006)及未行根治性切除者(<1%,1/2006),最终纳入1580例,平均随访37±22个月。
- 采用Kaplan-Meier生存分析按化疗后肿瘤坏死百分比分层评估5年生存,并行多因素Cox回归和多因素logistic回归分析。
主要发现
- 90%至94%坏死组5年总生存70%(95%CI 60.6%至79.7%),95%至100%坏死组74%(95%CI 68%至80.3%),两组无差异(p=0.47)。
- 坏死低于90%与更差生存相关(HR 2.00,95%CI 1.58至2.52,p<0.001,与超过90%坏死相比)。
- 与不良生存最相关的因素为转移(HR 2.85,95%CI 2.27至3.59,p<0.001)和诊断时跳跃转移(HR 2.52,95%CI 1.64至3.88,p<0.001)。
- 多因素分析中,无保险状态与达到90%以上坏死负相关(OR 0.46,95%CI 0.23至0.92,p=0.02,与私人保险相比)。
- 社会经济地位复合评分最低第一四分位OR 0.63(95%CI 0.44至0.90,p=0.01),第二四分位OR 0.70(95%CI 0.50至0.96,p=0.03)。
关键数值与推荐
- 90%至94%坏死组5年总生存70%(95%CI 60.6%至79.7%),95%至100%坏死组74%(95%CI 68%至80.3%),组间无差异(p=0.47)。
- 坏死低于90%与超过90%坏死相比,生存更差(HR 2.00,95%CI 1.58至2.52,p<0.001)。
- 转移与不良生存相关(HR 2.85,95%CI 2.27至3.59,p<0.001),诊断时跳跃转移与不良生存相关(HR 2.52,95%CI 1.64至3.88,p<0.001)。
- 无保险与达到90%以上坏死负相关(OR 0.46,95%CI 0.23至0.92,p=0.02,与私人保险相比)。
- 社会经济地位复合评分最低第一四分位OR 0.63(95%CI 0.44至0.90,p=0.01),第二四分位OR 0.70(95%CI 0.50至0.96,p=0.03)。
临床怎么用
- 作者认为,医疗服务提供者应了解这些关联以确保公平的医疗可及性和服务提供,因为医疗可及性可能解释这些关联。
- 作者建议,未来研究应探究该观察的潜在驱动因素,如就诊延迟或偏离标准治疗实践。
局限性
- NCDB仅允许为每位患者编码一个主要种族,因此大多数患者被分组为白人种族或黑人种族,其余被分组为其他种族进行分析。
- 尽管分析中控制了多个变量,但诸如种族等宽泛变量可能因未测量的混杂因素而与组织学反应相关。
- 这些关联必须被仔细理解,不应视为因果关系,而可能反映健康差异和医疗可及性的影响。
- 未来研究应探究该观察的潜在驱动因素,如就诊延迟或偏离标准治疗实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The histologic response of osteosarcoma to chemotherapy is commonly cited as a prognostic factor and typically graded as the percent necrosis of the tumor at the time of surgical resection. Few studies, to our knowledge, have examined the relationship of tumor necrosis relative to other factors. Existing studies are limited by prolonged enrollment periods or analysis of patient subsets without the strongest predictor of mortality: metastasis at diagnosis. Additionally, the definitive threshold value for a good histologic response is commonly set at more than 90% tumor necrosis with little evidence; some authors advocate other values. QUESTION/PURPOSES: (1) Are there alternative cutoff values for a good response to chemotherapy in a large, national cohort of contemporarily treated patients with osteosarcoma? (2) How does the association of histologic response to survival in osteosarcoma compare with other clinicopathologic factors? (3) What patient and clinical factors are associated with the histologic response? METHODS: We identified 2006 patients with osteosarcoma diagnosed between 2010 and 2015 in the National Cancer Database (NCDB), a registry that includes 70% of all new cancers diagnosed in the United States with 90% follow-up. Patients were excluded for missing documentation of percent tumor necrosis (21% [425 of 2006]) or if definitive resection was not performed (< 1% [1 of 2006]). A total of 1580 patients were included in the analysis, with a mean follow-up duration of 37 ± 22 months. A Kaplan-Meier survival analysis, stratified by the percent tumor necrosis after chemotherapy, was performed for the 5-year period. Other covariates examined were sex, race, socioeconomic score composite, insurance type, Charlson/Deyo score, distance from the hospital, and location (metropolitan, urban, or rural). Clinical and sociodemographic data including patient-identified race from the patient's medical record is input into the NCDB by certified registrars. The NCDB only allows coding of one primary race for each patient; thus, most of our patients were grouped as White or Black race and the remaining were grouped as Other for our analysis. A multiple Cox regression analysis was performed to evaluate the effect of percent necrosis compared with other demographic, clinicopathologic, and treatment effects on survival. Finally, a multiple logistic regression analysis was performed to assess demographic and clinicopathologic characteristics associated with percent necrosis. RESULTS: Five-year overall survival for patients with histologic gradings of 90% to 94% necrosis (70% [95% confidence interval (CI) 60.6% to 79.7%) and 95% to 100% necrosis (74% [95% CI 68% to 80.3%) was not different between groups (p = 0.47). A comparison of histologic responses below 90% necrosis found no difference in survival between patients with decreasing histologic response (p > 0.05). Necrosis of less than 90% was associated with worse survival (HR 2.00 [95% CI 1.58 to 2.52]; p < 0.001 compared with more than 90% necrosis), and factors most associated with poor survival were metastasis (HR 2.85 [95% CI 2.27 to 3.59]; p < 0.001) and skip metastasis at the time of diagnosis (HR 2.52 [95% CI 1.64 to 3.88]; p < 0.001). On multivariate analysis, adjusting for demographic, clinicopathologic, and treatment factors, social determinants of health were negatively associated with percent necrosis of 90% or more, including uninsured status (OR 0.46 [95% CI 0.23 to 0.92]; p = 0.02 compared with private insurance) and lower socioeconomic status composite (OR for the lowest first and second quartiles were 0.63 [95% CI 0.44 to 0.90]; p = 0.01 and 0.70 [95% CI 0.50 to 0.96]; p = 0.03, respectively). Race other than White or Black (OR 0.61 [95% CI 0.40 to 0.94]; p = 0.02 compared with White race) was also negatively associated with percent necrosis of more than 90% after controlling for available covariates. CONCLUSION: This study suggests that a cutoff of 90% necrosis provides the best prognostic value for patients with osteosarcoma undergoing chemotherapy. Other threshold values did not show different survival benefits. Sociodemographic factors were associated with histologic response less than 90%. These associations must be carefully understood not as cause and effect but likely demonstrating the effects of health disparities and access to care. Although we controlled for multiple variables in our analysis, broad variables such as race may have been associated with histologic response due to unaccounted confounders. Medical providers should be aware of these associations to ensure equitable access and delivery of care because access to care may be responsible for these associations. Future studies should examine potential drivers of this observation, such as a delay in presentation or deviation from standard of care practices. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Richardson SM, Wurtz LD, Collier CD, et al. Ninety Percent or Greater Tumor Necrosis Is Associated With Survival and Social Determinants of Health in Patients With Osteosarcoma in the National Cancer Database. Clin Orthop Relat Res. 2022. PMID: 36099400. doi:10.1097/CORR.0000000000002380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。